During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...
Qivigy (immune globulin intravenous, human-kthm) is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin for IV administration.
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who ...
Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four ... and urinary tract infection (10%). Delay BRIUMVI administration in patients with an ...
Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the ...
Commerce Secretary Howard Lutnick indicated the Trump administration is looking to take a cut of the revenue generated by university patents developed through federally funded research. Lutnick in an ...
In clinical trials, Imaavy plus standard therapy improved muscle strength and daily function in adults and adolescents with generalized myasthenia gravis.
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including ...
The Education Department announced Wednesday it is ending discretionary funding to multiple Minority-Serving Institutions (MSI) grant programs. The funding violated the law, according to the Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback